Clinical Operations Journal by Dx Direct

Point-of-Care Testing (POCT)

FebriDx Just Got a CLIA Waiver, Here’s What That Means for Your Clinic

Point-of-care tests are evolving quickly and that’s great news! In primary care clinics, urgent care centers and outpatient departments, there’s always a need to balance quick testing and accuracy. If you’ve ever seen a patient with symptoms like fever, sore throat, or cough, you know that you have to find answers for two questions: what’s wrong and how soon we can figure it out. The recent CLIA waiver for FebriDx is a meaningful step forward. It signals that this rapid test can now be used more broadly in clinical settings

Read More »

Simplifying Point-of-Care Adoption

Supporting better decisions without adding complexity.

FebriDx is intended to support clinical decision-making and must be interpreted in the context of signs, symptoms, patient history, and clinical judgment. It does not identify a specific pathogen and is not a standalone diagnostic.

FebriDx® is manufactured by Lumos Diagnostics. Dx Direct serves as an authorized distribution channel and does not manufacture the product.

© 2026. All Rights Reserved.